Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer

被引：0
|
作者：
Altunel, Erdem
Zokaasadi, Mohammad
Somarelli, Jason A.
McCall, Shannon J.
Gultawatvichai, Patan
Whalen, Giles Francis
Pitarresi, Jason
Hsu, David S.
机构：
[1] UMass Chan Med Sch, Div Hematol Oncol, Dept Med, Worcester, MA USA
[2] Duke Univ, Div Med Oncol, Dept Med, Med Ctr, Durham, NC USA
[3] Duke Univ, Dept Pathol, Med Ctr, Durham, NC USA
[4] UMass Chan Med Sch, Div Surg Oncol, Dept Surg, Worcester, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15601
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CDK12 Changes Telling in Prostate Cancer
    Caruso, Catherine
    CANCER DISCOVERY, 2018, 8 (09) : 1055 - 1056
  • [32] MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
    Pitolli, Consuelo
    Marini, Alberto
    Guerra, Marika
    Pieraccioli, Marco
    Marabitti, Veronica
    Palluzzi, Fernando
    Giaco, Luciano
    Tamburrini, Gianpiero
    Cecconi, Francesco
    Nazio, Francesca
    Sette, Claudio
    Pagliarini, Vittoria
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [33] Functions of Cdk12 and Cdk13 in axonal growth and neural development
    Fann, M-J
    Chen, H-R
    Lin, G-T
    Huang, C-K
    JOURNAL OF NEUROCHEMISTRY, 2014, 130 : 39 - 39
  • [34] CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer
    Lu, Ke-Qi
    Li, Zuo-Lin
    Zhang, Qian
    Yin, Qing
    Zhang, Yi-Lin
    Ni, Wei-Jie
    Jiang, LiangYun-Zi
    He, Wei
    Wang, Bin
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [35] CDK12 and PAK2 as novel therapeutic targets for human gastric cancer
    Liu, Hui
    Shin, Seung Ho
    Chen, Hanyong
    Liu, Tingting
    Li, Zhi
    Hu, Yamei
    Liu, Fangfang
    Zhang, Chengjuan
    Kim, Doon Jun
    Liu, Kangdong
    Dong, Zigang
    THERANOSTICS, 2020, 10 (14): : 6201 - 6215
  • [36] Targeting CDK12 is a novel therapeutic strategy through disrupting oncogene associated super-enhancers in metastatic colorectal cancer
    Kuang, Zhijian
    Wong, Chun-Ming
    CLINICAL AND TRANSLATIONAL DISCOVERY, 2022, 2 (04):
  • [37] CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer
    Lotan, Tamara L.
    Antonarakis, Emmanuel S.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 380 - 382
  • [38] Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
    Chang, Yu
    Wang, Xiaoju
    Yang, Jianzhang
    Tien, Jean Ching-Yi
    Mannan, Rahul
    Cruz, Gabriel
    Zhang, Yuping
    Vo, Josh N.
    Magnuson, Brian
    Mahapatra, Somnath
    Cho, Hanbyul
    Dhanasekaran, Saravana Mohan
    Wang, Cynthia
    Wang, Zhen
    Zhou, Licheng
    Zhou, Kaijie
    Zhou, Yang
    Zhang, Pujuan
    Huang, Weixue
    Xiao, Lanbo
    Liu, Weihuang Raymond
    Hamadeh, Rudana
    Su, Fengyun
    Wang, Rui
    Miner, Stephanie J.
    Cao, Xuhong
    Cheng, Yunhui
    Mehra, Rohit
    Ding, Ke
    Chinnaiyan, Arul M.
    CELL REPORTS, 2024, 5 (10):
  • [39] CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer
    Li, Yi
    Zhang, Hui
    Li, Qin
    Zou, Pingjin
    Huang, Xingxiang
    Wu, Chihua
    Tan, Li
    CANCER LETTERS, 2020, 495 : 12 - 21
  • [40] Synthetic lethality of CDK12 inhibition in tumors with EWS/FLI rearrangements
    Balboni, Amanda L.
    Stolte, Bjorn
    Conway, Amy Saur
    Alexe, Gabriela
    Wang, Emily Jue
    Kwiatkowski, Nicholas
    Zhang, Tinghu
    Abraham, Brian J.
    Kalev, Peter
    Chowdhury, Dipanjan
    Benes, Cyril H.
    Young, Richard A.
    Gray, Nathanael S.
    Stegmaier, Kimberly
    CANCER RESEARCH, 2017, 77
12345